Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;26(6):1436-9.
doi: 10.1038/leu.2011.373. Epub 2012 Jan 6.

Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model

E Van Valckenborgh, W Matsui, P Agarwal, S Lub, X Dehui, E De Bruyne, E Menu, C Empsen, L van Grunsven, J Agarwal, Q Wang, H Jernberg-Wiklund, K Vanderkerken

Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model

E Van Valckenborgh et al. Leukemia. 2012 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) CD138 expression on 5T33 MM cells analyzed by flow cytometry. Purified 5T33 MM cells were analyzed by a membranic staining with PE labeled anti-CD138 and simultaneous staining with anti-5T33 MM idiotype antibodies, which were detected with rat anti-mouse IgG1-APC. Irrelevant isotype controls were used as control. Dot plot represents anti-idiotype and anti-CD138 staining of events gated on 7AAD- living cells. (b, c) B-cell lymphoma 6 (Bcl-6), B-lymphocyte-induced maturation protein 1 (Blimp-1), X-box binding protein-1 (Xbp-1) and Interferon regulatory factor 4 (IRF4) expression in 5T33 MM and 5TGM1 sorted CD138− cells compared with CD138+ cells. Real-time Q-PCR showing fold increase/decrease of mRNA levels in CD138− samples compared with CD138+ samples (equal to 1). To standardize the amount of sample RNA, we used an endogenous reference gene. Results of one independent sample of three are shown. Primer sequences are available upon request. (d) Expression of EZH2, SUZ12 and EED in the 5T33 MM CD138− cells compared with CD138+ cells. Real-time Q-PCR showing fold increase/decrease of mRNA levels in CD138− samples compared with CD138+ samples (equal to 1). To standardize the amount of sample RNA, we used an endogenous reference gene. Results shown are combined from two independent samples repeated twice. Primer sequences are available upon request. (e) Clonogenicity of CD138− and CD138+ populations in 5T33 MM model. Sorted populations were plated in methylcellulose medium at a concentration of 5×104/ml. After 10 days incubation at 37 °C and 5% CO2, the number of colonies was counted. The mean value±s.d. of two (5T33 MM) and three (5TGM1) independent experiments is shown.
Figure 2
Figure 2
(a) Tumor engraftment studies with CD138− and CD138+ populations of 5T33 MM. (b) Drug sensitivity of CD138− and CD138+ 5T33 MM cells. Sorted populations were incubated with bz, MG132, LBH589 and 17AAG at the indicated concentrations. After 20 h, the viability was measured by the CellTiter-Glo Luminescent Viability Assay. Results are given as the percentage viability relative to control (100%). Each dot represents the result of an independent experiment. *Indicates P-value<0.05 (Mann–Whitney test). (c) Percentage CD138− cells after bz treatment in vivo measured with flow cytometry. Results shown are from five mice in each group. Differences between vehicle and bz-treated group are significant (P<0.008, Mann–Whitney test).
See this image and copyright information in PMC

References

    1. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009;23:449–456. - PMC - PubMed
    1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. - PubMed
    1. Rasmussen T, Lodahl M, Hancke S, Johnsen HE. In multiple myeloma clonotypic CD38− /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma. 2004;45:1413–1417. - PubMed
    1. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26:2895–2900. - PMC - PubMed
    1. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196–206. - PubMed

Publication types